MicroPort CardioFlow Medtech Past Earnings Performance
Past criteria checks 0/6
MicroPort CardioFlow Medtech's earnings have been declining at an average annual rate of -23.9%, while the Medical Equipment industry saw earnings growing at 10.9% annually. Revenues have been growing at an average rate of 36.4% per year.
Key information
-23.9%
Earnings growth rate
-17.1%
EPS growth rate
Medical Equipment Industry Growth | 13.7% |
Revenue growth rate | 36.4% |
Return on equity | -20.2% |
Net Margin | -140.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MicroPort CardioFlow Medtech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 336 | -472 | 293 | 237 |
30 Sep 23 | 319 | -491 | 273 | 246 |
30 Jun 23 | 303 | -511 | 253 | 254 |
31 Mar 23 | 277 | -483 | 243 | 239 |
31 Dec 22 | 251 | -454 | 233 | 224 |
30 Sep 22 | 245 | -345 | 213 | 203 |
30 Jun 22 | 239 | -236 | 193 | 182 |
31 Mar 22 | 220 | -209 | 173 | 166 |
31 Dec 21 | 201 | -183 | 152 | 151 |
30 Sep 21 | 176 | -265 | 131 | 133 |
30 Jun 21 | 151 | -346 | 111 | 116 |
31 Mar 21 | 128 | -372 | 104 | 106 |
31 Dec 20 | 104 | -398 | 97 | 97 |
31 Dec 19 | 22 | -145 | 37 | 97 |
Quality Earnings: 2160 is currently unprofitable.
Growing Profit Margin: 2160 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2160 is unprofitable, and losses have increased over the past 5 years at a rate of 23.9% per year.
Accelerating Growth: Unable to compare 2160's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2160 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-8.3%).
Return on Equity
High ROE: 2160 has a negative Return on Equity (-20.2%), as it is currently unprofitable.